DHR vs PFE: Which Is the Better Buy?

Side-by-side comparison of Danaher Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-06-20.
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
DHR has more upside to fair value (+8.9%). PFE trades at a lower forward P/E (19.2x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric DHR PFE
Current Price $177.17 $25.22
Fair Value Estimate $192.90 $25.92
Upside to Fair Value +8.9% +2.8%
Market Cap $125.4B $143.7B
Forward P/E 34.1x 19.2x
EV / EBITDA 20.8x 12.3x
Price / Sales 5.1x 2.3x
Price / FCF 23.7x 15.2x
Revenue Growth YoY +3.7% +5.4%
Gross Margin 60.7% 69.3%
Operating Margin 21.0% 23.4%
Return on Equity 7.1% 8.4%
Dividend Yield 0% 0%
FCF Yield 4.22% 6.6%
Analyst Consensus Strong Buy Hold
Investment Thesis
DHR — Danaher Corporation
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
PFE — Pfizer Inc.
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
Metric DHR PFE
Zone Low $144.68 $19.44
Zone High $163.97 $22.03
In Buy Zone? No No
← DHR Research    PFE Research →    All Research